×

Stocks Johnson & Johnson

  • Stocks shot out of the gate Monday, fueled by earnings optimism, but then pulled back near the final hour of trading as investors took some profits.

  • Going by historical precedent and recent chart strength, Johnson & Johnson leads a list of companies most likely to beat Street estimates and subsequently trade higher.

  • Two and a half months away from the end of the year and the average dividend yield of the Dow 30 has continued to fall since the market lows.  See how the 30 companies in the Dow compare.

  • MM_promo_Cramerica_Challenge_530x50.jpg

    A “ton of upside” is in store for this stock, Cramer says. Find out why.

  • MM_promo_Cramerica_Challenge_530x50.jpg

    It’s all about the earnings, he says. These are the companies you need to watch.

  • The global recovery is being led by countries outside of the United States, and investors should look to multinational corporations to protect themselves against the weakening dollar, said David Darst of Morgan Stanley Smith Barney.

  • Following are the week’s biggest winners and losers. Find out why shares of Newmont and Wells Fargo popped while Acorda Therap. and the iShares 20 Year Treas. ETF  dropped.

  • The S&P 500 is up 4 percent this week, it's best gain in a long time, and it's a simple story: Alcoa and a number of retailers are all signaling that the economy is slowly improving, and for the moment "slowly" is good enough for the stock market.

  • Can the bulls can generate enough momentum to drive the Dow over 10,000 next week, or are they're about to be sidelined by the dollar?

  • alcoa1_new.jpg

    Third-quarter earnings got off to a positive start with Alcoa's surprising profit, but investors will be watching corporate results closely to see if they justify a continued stock market rally.

  • EarningsCentral_20081022.jpg

    As Wall Street contemplates whether to rally or retreat, third-quarter earnings could be what settles the debate.

  • Playing the volatility of the health care sector while legislation is still pending in Congress could be profitable, especially in managed care, Les Funtleyder, health care strategist at Miller Tabak, told CNBC.

  • yen_euro_dollar.jpg

    Investors who capitalized on the market's amazing six-month run are now going to want to find a way to protect their profits.

  • The third quarter has past and for investors seeking dividends, they can be glad.  Standard & Poor's said yesterday that third-quarter dividend increases this year were the worst on record. Dividend payments during the third quarter fell 44.8% from a year ago, with only 191 of about 7,000 public companies -tracked by S&P- increasing their payouts.

  • Stocks logged their best quarter in 11 years, helped  by the weak dollar, despite today's soft landing.

  • We know it seems like the Fast Money moves at the speed of light. So we thought you’d appreciate it if we slowed things down a bit.Following you’ll find Fast Money’s Slow Money trades – stocks the traders would buy and hold for the next five years!

    We thought you’d appreciate it if we slowed things down a bit.  Here you’ll find Fast Money’s Slow Money trades – stocks the traders would buy and hold for the next five years!

  • Stocks retreated Tuesday as weak readings on manufacturing and jobs offset a a report that showed the economy wasn't in as bad a shape as first expected over the summer.

  • Futures indicated a positive open for Wall Street on Tuesday, the last day of the third quarter, as European stocks rose and were set to lock in their best quarterly performance in nearly a decade.

  • Despite a pull back in the U.S. equity markets last week, the S&P and Nasdaq Composite are having their best September since 1998 so far, while the Dow is on track for its biggest % gain in September since 2007.  Even though September ranks as the worst month historically on average for all three indices, the Nasdaq Composite has traded up 12 sessions out of 19 as of Monday's close while the Dow and S&P have finished up 11 days of 19.

  • Investors are placing their bets on the next M&A deal in biotech. Where should you be looking?